Ki-67 Staining Is a Strong Predictor of Distant Metastasis and Mortality for Men With Prostate Cancer Treated With Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92–02

A Pollack; M DeSilvio; L.-Y Khor; R Li; T.I Al-Saleem; M.E Hammond; V Venkatesan; C.A Lawton; M Roach; W.U Shipley; G.E Hanks; H.M Sandler

doi:10.1200/JCO.2004.09.150

Back

Ki-67 Staining Is a Strong Predictor of Distant Metastasis and Mortality for Men With Prostate Cancer Treated With Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92–02

Journal article

Peer reviewed

Ki-67 Staining Is a Strong Predictor of Distant Metastasis and Mortality for Men With Prostate Cancer Treated With Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92–02

A Pollack, M DeSilvio, L.-Y Khor, R Li, T.I Al-Saleem, M.E Hammond, V Venkatesan, C.A Lawton, M Roach, W.U Shipley, …

Journal of clinical oncology, Vol.22(11), pp.2133-2140

2004-06-01

DOI: https://doi.org/10.1200/JCO.2004.09.150

PMID: 15169799

Abstract

Purpose The Ki-67 staining index (Ki67-SI) has been associated with prostate cancer patient outcome; however, few studies have involved radiotherapy (RT) -treated patients. The association of Ki67-SI to local failure (LF), biochemical failure (BF), distant metastasis (DM), cause-specific death (CSD) and overall death (OD) was determined in men randomly assigned to short term androgen deprivation (STAD) + RT or long-term androgen deprivation (LTAD) + RT. Patients and Methods There were 537 patients (35.5%) on Radiation Therapy Oncology Group (RTOG) 92-02 who had sufficient tissue for Ki67-SI analysis. Median follow-up was 96.3 months. Ki67-SI cut points of 3.5% and 7.1% were previously found to be related to patient outcome and were examined here in a Cox proportional hazards multivariate analysis (MVA). Ki67-SI was also tested as a continuous variable. Covariates were dichotomized in accordance with stratification and randomization criteria. Results Median Ki67-SI was 6.5% (range, 0% to 58.2%). There was no difference in the distribution of patients in the Ki-67 analysis cohort (n = 537) and the other patients in RTOG 92-02 (n = 977) by any of the covariates or end points tested. In MVAs, Ki67-SI (continuous) was associated with LF (P = .08), BF (P = .0445), DM (P < .0001), CSD (P < .0001), and OD (P = .0094). When categoric variables were used in MVAs, the 3.5% Ki67-SI cut point was not significant. The 7.1% cut point was related to BF (P = .09), DM (P = .0008), and CSD (P = .017). Ki67-SI was the most significant correlate of DM and CSD. A detailed analysis of the hazard rates for DM in all possible covariate combinations revealed subgroups of patients treated with STAD + RT that did not require LTAD. Conclusion Ki67-SI was the most significant determinant of DM and CSD and was also associated with OD. The Ki67-SI should be considered for the stratification of patients in future trials.

Metrics

43 Record Views

131 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.147 Prostate Cancer; 1.147.97 Prostate Cancer
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Ki-67 Staining Is a Strong Predictor of Distant Metastasis and Mortality for Men With Prostate Cancer Treated With Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92–02
Creators: A Pollack - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
M DeSilvio - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
L.-Y Khor - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
R Li - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
T.I Al-Saleem - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
M.E Hammond - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
V Venkatesan - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
C.A Lawton - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
M Roach - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
W.U Shipley - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
G.E Hanks - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
H.M Sandler - From the Departments of Radiation Oncology and Pathology, Fox Chase Cancer Center; Department of Biostatistics, American College of Radiology (RTOG), Philadelphia, PA; Department of Pathology, Baylor School of Medicine, Houston, TX; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT; Department of Radiation Oncology, University of Western Ontario, London, ON, Canada; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation
Publication Details: Journal of clinical oncology, Vol.22(11), pp.2133-2140
Academic Unit: Leadership Department; Miller School of Medicine; UMMG Dept of Radiation Oncology
Language: English
Resource Type: Journal article
PMID: 15169799
Record Identifier: 991031559389402976